Harrow, Inc. (HROW) Dividend History

Harrow, Inc. (HROW) is a medical technology company specializing in the development and commercialization of advanced microneedle-based systems for the delivery of pharmaceuticals, vaccines, and other therapeutics. The company's innovative approaches aim to improve patient care through minimally invasive, pain-free, and efficient drug administration methods. Harrow's products are designed to enhance compliance, reduce administration costs, and expand access to vital treatments.

102 Woodmont Blvd, Nashville, TN, 37215
Phone: 615.733.4731
Website: https://www.harrow.com

Dividend History

Harrow, Inc. currently does not pay dividends

Company News

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox announced that the last patient has completed the final visit in the Whistler Phase 3b clinical trial for its lead product candidate NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The results of the Denali Phase 3 trial are also expected in Q3 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROWL HROWM
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.

Benzinga

Featured Companies: BKKT BON GES GETY HQY HROWL HROWM IHS QQQ SGMO SPY STN
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox presented additional analysis from the NCX 470 Mont Blanc Phase 3 trial, showing that more patients on NCX 470 achieved an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost. The company also provided an update on the development of NCX 470, including plans for a U.S. New Drug Application submission targeted in H1 2026.

GlobeNewswire Inc.

Featured Companies: BLCO HROWL HROWM
Nicox : Présentation Scientifique et Participation aux Congrès du premier semestre 2025

Nicox, a specialty ophthalmology company, announces a poster presentation at the American Glaucoma Society Congress and participation in several key ophthalmology and finance conferences in the first half of 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROWL HROWM
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Nicox, an international ophthalmology company, announced a presentation at the American Glaucoma Society Annual Meeting 2025 and participation in several key ophthalmology and financial conferences in the first half of 2025.

GlobeNewswire Inc.

Featured Companies: BLCO HROWL HROWM

Dividend data last updated 06/06/2025 20:27:25 UTC